Novartis Buys into New Pharma World Order
Executive Summary
In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.
You may also be interested in...
Novartis Plans to Move Infectious Disease Research Group to the Bay Area
The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.
Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope
As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.
Novartis Gets Bricks And Mortar Money: Last Vaccine Support From Bush Administration
Commercial production at North Carolina facility supported by the HHS grant is at least three years away.